2024
P101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study
Wang Z, Yang M, Chao J, Martins B, Chuang C, Shumel B, Sierka D, Carboni M, Strober B. P101 Sustained improvement in atopic dermatitis disease control and treatment satisfaction with dupilumab in clinical practice: 4-year follow-up results from the RELIEVE-AD study. British Journal Of Dermatology 2024, 191: i63-i64. DOI: 10.1093/bjd/ljae090.128.Peer-Reviewed Original ResearchAtopic dermatitisEpisodes of itchingTreatment satisfactionMonth 1Disease controlClinical practiceProportion of patientsPatient survey studyPercentage of patientsSustained improvementFollow-up resultsPrescribed dupilumabGeneralized estimating equationsQuality of lifePatient support programmeSingle-armDupilumabSkin symptomsBaseline surveyPatientsSupport programmesPatient satisfactionPractice guidelinesStatistical significanceMonths
2023
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
Kimball A, Delevry D, Yang M, Chuang C, Wang Z, Bégo-Le-Bagousse G, Martins B, Wu E, Shumel B, Wang J, Sierka D, Chao J, Strober B. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study. Dermatology And Therapy 2023, 13: 2107-2120. PMID: 37552431, PMCID: PMC10442302, DOI: 10.1007/s13555-023-00965-5.Peer-Reviewed Original ResearchPatient-reported outcomesAtopic Dermatitis Control ToolAD therapyDermatology Life Quality IndexActivity Impairment QuestionnaireLong-term therapyLife Quality IndexLong-term treatmentPatient-reported benefitsPatient support programClinical practice settingReal-world studyAdequate disease controlLong-term effectivenessDupilumab useImpairment QuestionnaireSevere ADAD medicationsAtopic dermatitisTherapy useSkin symptomsCurrent therapiesSleep problemsDupilumabPractice settings
2022
33322 Dupilumab improves patient-reported outcomes among adults with moderate-to-severe atopic dermatitis (AD) in clinical practice: 30-36 month results from the RELIEVE-AD study
Strober B, Chao J, Chuang C, Yang M, Shumel B, Wang J, Bego-Le-Bagousse G, Sierka D, Wang Z, Delevry D. 33322 Dupilumab improves patient-reported outcomes among adults with moderate-to-severe atopic dermatitis (AD) in clinical practice: 30-36 month results from the RELIEVE-AD study. Journal Of The American Academy Of Dermatology 2022, 87: ab159. DOI: 10.1016/j.jaad.2022.06.669.Peer-Reviewed Original Research